Xeris Biopharma Holdings, Inc. XERS
9.10
0.15
1.68%
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow XERS
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 78.59 | 2,065.79 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.08 | 3.14 | 4.32 | 5.01 | |
P/FCF ratio |
24.59 | 20.81 | 45.09 | 133.55 | |
P/Operating CF |
165.65 | 100.21 | 62.83 | 72.27 | |
P/B ratio |
0.00 | 76.02 | 92.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.47 | 3.53 | 4.73 | 5.53 | |
EV/EBITDA |
28.35 | 21.32 | 33.70 | 57.14 | |
EV/Operating CF |
26.49 | 22.88 | 48.23 | 139.41 | |
EV/FCF |
26.94 | 23.37 | 49.43 | 147.56 | |
Quick Ratio |
0.95 | 1.42 | 1.48 | 1.25 | |
Current Ratio |
1.45 | 2.12 | 2.19 | 1.93 | |
Net Debt/EBITDA |
14.08 | 9.11 | 5.25 | 11.88 | |
Debt/Assets |
61.32% | 56.43% | 57.45% | 59.29% | |
Debt/Equity |
(25.95) | 17.00 | 16.10 | (254.90) | |
Asset Turnover |
0.90 | 0.89 | 0.83 | 0.77 | |
Operating CF/Net income |
(0.27) | 4.42 | 1.81 | 29.68 | |
Capex/Depreciation |
(0.05) | (0.08) | (0.08) | (0.02) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
11.58% | 10.57% | 9.18% | 10.06% | |
Selling, General and Administrative Expense of Revenue |
66.27% | 63.93% | 55.36% | 62.46% | |
Intangible Assets out of Total Assets |
0.26 | 0.28 | 0.29 | 0.31 | |
Share Based Compensation of Revenue |
12.02% | 4.98% | 6.14% | 10.28% | |
Graham Net Nets |
(0.11) | (0.13) | (0.10) | (0.11) | |
Graham Number |
0.35 | 0.36 | 0.09 | 0.11 | |
Earnings Yield |
(1.21%) | 1.27% | 0.05% | (1.18%) | |
Free Cash Flow Yield |
4.07% | 4.80% | 2.22% | 0.75% | |
Revenue per Share |
0.53 | 0.49 | 0.53 | 0.45 | |
Operating CF per Share |
0.05 | 0.06 | 0.12 | 0.11 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.05 | 0.06 | 0.12 | 0.11 | |
Cash per Share |
0.70 | 0.66 | 0.69 | 0.56 | |
Shareholders Equity per Share |
(0.06) | 0.08 | 0.09 | (0.01) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.06) | 0.08 | 0.09 | (0.01) | |
Free Cash Flow |
8.05 | 9.55 | 19.71 | 18.36 | |
Working Capital |
85.19 | 133.09 | 130.74 | 107.82 | |
Capital Expenditures |
(0.21) | (0.32) | (0.33) | (0.07) | |
Net Current Asset Value |
(146.88) | (127.32) | (129.52) | (147.03) | |
EV/EBIT |
40.98 | 30.93 | 55.45 | 150.17 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(33.77%) | 2.69% | 12.91% | 0.83% | |
Price to Operating Income |
37.40 | 27.55 | 50.58 | 135.90 | |
| Other line items | |||||
Average Receivables |
55.58 | 51.31 | 45.73 | 47.44 | |
Average Payables |
9.40 | 8.91 | 2.68 | 6.99 | |
Average Inventory |
74.11 | 63.46 | 58.42 | 56.29 | |
Average Assets |
373.30 | 353.73 | 353.29 | 345.65 | |
Average Common Equity |
(14.52) | (11.06) | (7.96) | (14.59) |
Columns are period end dates